Dexrazoxane reduces antithrombin activity: a case series.

IF 0.4 Q4 ONCOLOGY

International Cancer Conference Journal Pub Date : 2026-02-13 eCollection Date: 2026-04-01 DOI:10.1007/s13691-026-00848-4

Tomohiro Nagano, Kaho Makiuchi, Akifumi Matsumura, Daigo Niiya, Soichiro Fujii, Makoto Takeuchi

{"title":"Dexrazoxane reduces antithrombin activity: a case series.","authors":"Tomohiro Nagano, Kaho Makiuchi, Akifumi Matsumura, Daigo Niiya, Soichiro Fujii, Makoto Takeuchi","doi":"10.1007/s13691-026-00848-4","DOIUrl":null,"url":null,"abstract":"Dexrazoxane prevents anthracycline-induced cardiotoxicity and treats anthracycline extravasation. Although thrombosis is not a commonly observed adverse effect of dexrazoxane, a potential association has been suggested. We present three patients (four episodes) who experienced decreased antithrombin activity after dexrazoxane administration. All patients were prescribed dexrazoxane to protect soft tissues from anthracycline extravasation during chemotherapy for hematological malignancies. This led to a reduction in antithrombin activity after a median of 4 days from the first dexrazoxane injection. The activity levels recovered several days later, and one patient developed deep-vein thrombosis. There was no apparent explanation other than dexrazoxane use, raising the possibility that dexrazoxane may be associated with decreased antithrombin activity. We hypothesize that this decrease in antithrombin activity may contribute to thrombosis after dexrazoxane injection. Based on these cases and a review of previous reports on dexrazoxane and thrombosis, it is recommended that clinicians monitor antithrombin decline and thrombosis development in patients undergoing dexrazoxane treatment.Supplementary information: The online version contains supplementary material available at 10.1007/s13691-026-00848-4.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 2","pages":"229-233"},"PeriodicalIF":0.4000,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038823/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-026-00848-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Dexrazoxane prevents anthracycline-induced cardiotoxicity and treats anthracycline extravasation. Although thrombosis is not a commonly observed adverse effect of dexrazoxane, a potential association has been suggested. We present three patients (four episodes) who experienced decreased antithrombin activity after dexrazoxane administration. All patients were prescribed dexrazoxane to protect soft tissues from anthracycline extravasation during chemotherapy for hematological malignancies. This led to a reduction in antithrombin activity after a median of 4 days from the first dexrazoxane injection. The activity levels recovered several days later, and one patient developed deep-vein thrombosis. There was no apparent explanation other than dexrazoxane use, raising the possibility that dexrazoxane may be associated with decreased antithrombin activity. We hypothesize that this decrease in antithrombin activity may contribute to thrombosis after dexrazoxane injection. Based on these cases and a review of previous reports on dexrazoxane and thrombosis, it is recommended that clinicians monitor antithrombin decline and thrombosis development in patients undergoing dexrazoxane treatment.

Supplementary information: The online version contains supplementary material available at 10.1007/s13691-026-00848-4.

查看原文本刊更多论文

Dexrazoxane降低抗凝血酶活性：一个病例系列。

右唑嗪可预防蒽环类药物引起的心脏毒性并治疗蒽环类药物外渗。虽然血栓形成并不是dexrazoxane常见的不良反应，但可能存在关联。我们报告了三名患者（四次发作），他们在给予右唑嗪后抗凝血酶活性下降。所有患者在血液学恶性肿瘤化疗期间均给予右唑嗪以保护软组织免受蒽环类药物外渗。这导致抗凝血酶活性在第一次右唑嗪注射后中位4天后降低。几天后活动水平恢复，一名患者出现了深静脉血栓。除了使用右唑嗪外，没有其他明显的解释，这增加了右唑嗪可能与抗凝血酶活性降低有关的可能性。我们假设这种抗凝血酶活性的降低可能有助于右唑嗪注射后血栓形成。基于这些病例和对先前关于右拉唑烷和血栓形成的报道的回顾，建议临床医生监测接受右拉唑烷治疗的患者抗凝血酶下降和血栓形成。补充信息：在线版本包含补充资料，下载地址：10.1007/s13691-026-00848-4。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)